CORV Correvio Pharma Corp.

0.36
-0.01  -3%
Previous Close 0.37
Open 0.37
Price To Book 13.92
Market Cap 18,096,757
Shares 55,382,228
Volume 2,533,326
Short Ratio
Av. Daily Volume 3,816,656
Stock charts supplied by TradingView

NewsSee all news

  1. Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events

    NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 24, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has

  2. Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value

    NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 11, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced plans to

  3. Correvio Announces Outcome Of FDA Advisory Committee Meeting Reviewing Brinavess™ For The Treatment Of Recent Onset Atrial Fibrillation

    NASDAQ: CORV    TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the

  4. Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation

    NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ

  5. Correvio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    NASDAQ: CORV   TSX: CORV VANCOUVER, Nov. 25, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL announced December 24, 2019.
Brinavess
Atrial fibrillation (AF)
PDUFA date April 27, 2020. NOTE: NDA was submitted by UTHR which holds rights to U.S. sales. CORV has rights to only European rights so will not be financially impacted by PDUFA decision but some stock price effect might be seen due to its upcoming European regulatory filing.
Trevyent
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events

    NASDAQ: CORV TSX: CORV VANCOUVER, Dec. 24, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has

  2. Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value

    NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 11, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced plans to

  3. Correvio Announces Outcome Of FDA Advisory Committee Meeting Reviewing Brinavess™ For The Treatment Of Recent Onset Atrial Fibrillation

    NASDAQ: CORV    TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the

  4. Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess™ For Recent Onset Atrial Fibrillation

    NASDAQ: CORV   TSX: CORV VANCOUVER, Dec. 10, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that NASDAQ

  5. Correvio to Present at the Piper Jaffray 31st Annual Healthcare Conference

    NASDAQ: CORV   TSX: CORV VANCOUVER, Nov. 25, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark

  6. Correvio Announces Presentation of New Brinavess™ Spectrum Data at the American Heart Association 2019 Annual Meeting

    NASDAQ: CORV   TSX: CORV Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting Safety Outcomes of Interest Observed in Less Than 1% Cases; No Deaths Reported Greater Than 70% of Atrial

  7. Correvio Reports Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV FDA Accepts Brinavess™ New Drug Application Advisory Committee Date Set for December 10, 2019 PDUFA Date Set for December 24, 2019 Management to Host Conference Call and Webcast Today, November

  8. Correvio to Report Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV Conference Call Scheduled for Thursday, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Nov. 7, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV,

  9. Correvio to Report Third Quarter 2019 Financial Results

    NASDAQ: CORV  TSX: CORV Conference Call Scheduled for Thursday, November 14, 2019 at 8:30 a.m. Eastern (5:30 a.m. Pacific) VANCOUVER, Nov. 7, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a

  10. Correvio Announces FDA Advisory Committee Meeting to Review Brinavess™ for Recent Onset Atrial Fibrillation

    NASDAQ: CORV   TSX: CORV VANCOUVER, Nov. 4, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that the

  11. Correvio to Present at the 2019 Cantor Global Healthcare Conference

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 27, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark H.N.

  12. Correvio to Present at the 2019 Cantor Global Healthcare Conference

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 27, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Mark

  13. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the

  14. Correvio Highlights FDA Acceptance of United Therapeutics' Trevyent New Drug Application

    NASDAQ: CORV   TSX: CORV VANCOUVER, Sept. 12, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV) (TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that the U.S.

  15. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /CNW/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin Renz,

  16. Correvio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NASDAQ: CORV  TSX: CORV VANCOUVER, Sept. 4, 2019 /PRNewswire/ - Correvio Pharma Corp. (NASDAQ:CORV, TSX:CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that Justin

  17. Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV   TSX:

  18. Correvio Announces Presentation Of Brinavess® Spectrum Data At The European Society Of Cardiology 2019 Congress

    Safety Outcomes of Interest Observed in Less Than 1% Cases; Zero Deaths Reported Greater Than 70% of Atrial Fibrillation Episodes Successfully Converted to Sinus Rhythm in a Median Time of 12 Minutes NASDAQ: CORV   TSX: